CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Kelonia Therapeutics, Inc.
AVM Biotechnology Inc
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Georgetown University
Acerta Pharma BV
National Institutes of Health Clinical Center (CC)
Assistance Publique - Hôpitaux de Paris
Cellectar Biosciences, Inc.
Center for International Blood and Marrow Transplant Research
Azienda Ospedaliero-Universitaria di Parma
Azienda Ospedaliero-Universitaria di Parma
Baylor College of Medicine
Children's Oncology Group
Mayo Clinic
Cancer Research UK
University Health Network, Toronto
Pierre Fabre Medicament
Pierre Fabre Medicament
University of Heidelberg Medical Center
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
Emory University
Center for International Blood and Marrow Transplant Research
University of Michigan Rogel Cancer Center